Inhibition of galectin-1 sensitizes hras-driven tumor growth to rapamycin treatment

Anticancer Research

Volumn 36, Issue 10, 2016, Pages 5053-5061

  Michael, James V ^a   Wurtzel, Jeremy G T ^a   Goldfinger, Lawrence E ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Dual inhibition; ERK; Galectin; MTOR; Rapamycin; RAS

Indexed keywords

GALECTIN 1; LIPID; MITOGEN ACTIVATED PROTEIN KINASE; OTX 008; RAPAMYCIN; RAS PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CALIXARENE; COMPOUND 0118; GREEN FLUORESCENT PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN P21; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASMS; NIH 3T3 CELL LINE; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CALIXARENES; FEMALE; GALECTIN 1; GREEN FLUORESCENT PROTEINS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPROTEIN COMPLEXES; NEOPLASMS; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS P21(RAS); SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84991769386     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11074     Document Type: Article

References (21)

1. Fernández-Medarde A and Santos E: Ras in cancer and developmental diseases. Genes Cancer 2: 344-358, 2011.
2. Mendoza M, Er EE and Blenis J: The RAS-ERK and PI3KmTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328, 2011.
3. Cheng CM, Li H, Gasman S, Huang J, Schiff R and Chang EC: Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Mol Cell Biol 31: 983-997, 2010.
4. Pylayeva-Gupta Y, Grabocka E and Bar-Sagi D: RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774, 2011.
5. Memmott R and Dennis PA: AKT-dependent and-independent mechanisms of mTOR regulation in cancer. Cell Signal 21: 656-664, 2009.
6. Ahearn IM, Haigis K, Bar-Sagi D, and Philips MR: Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 13: 39-51, 2012.
7. Prior IA, Harding A, Yan J, Sluimer J, Parton RG, and Hancock JF: GTP-dependent segregation of H-RAS from lipid rafts is required for biological activity. Nat Cell Biol 3: 368-375, 2001.
8. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E and Faivre S: Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 40: 307-319, 2014.
9. Belanis L, Plowman SJ, Rotblat B, Hancock JF and Kloog Y: Galectin-1 is a novel structural component and a major regulator of H-Ras nanoclusters. Mol Biol Cell 19: 1404-1414, 2008.
10. Paz A, Haklai R, Elad-Sfadia G, Ballan E and Kloog Y: Galectin-1 binds oncogenic H-RAS to mediate RAS membrane anchorage and cell transformation. Oncogene 20: 7486-7493, 2001.
11. Prior I, Muncke C, Parton RG and Hancock JF: Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 160: 165-170, 2003.
12. Michael JV, Wurtzel JG, and Goldfinger LE: Regulation of HRAS-driven MAPK signaling, transformation and tumorigenesis, but not Pi3k signaling and tumor progression, by plasma membrane microdomains. Oncogenesis 5: e228, 2016.
13. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD and DePinho RA: Essential role for oncogenic RAS in tumour maintenance. Nature 400: 468-472, 1999.
14. Baines A, Xu D and Der CJ: Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 3: 1787-1808, 2011.
15. Holderfield M, Deuker MM, McCormick F and McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14: 455-467, 2014.
16. Wurtzel JG, Kumar P, and Goldfinger LE: Palmitoylation regulates vesicular trafficking of R-Ras to membrane ruffles and effects on ruffling and cell spreading. Small GTPases 3: 139-153, 2012.
17. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, and Cichowski K: TORC1 is essential for NF1-associated malignancies. Curr Biol 18: 56-62, 2008.
18. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, Vidaud M, de Gramont A, Martinet M, Cvitkovic E, Faivre S and Raymond E: OTX008, a selective small-molecule inhibitor of galectin-1, down-regulates cancer cell proliferation, invasion and tumour angiogenesis. Eur J Cancer 50: 2463-2477, 2014.
19. Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, Cvitkovic E, Noel K, Ubezio P, Giavazzi R, D'Incalci M and Taraboletti G: Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol 72: 879-887, 2013.
20. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ and Kloog Y: Galectin-1 augments RAS activation and diverts RAS signals to RAF-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 277: 37169-37175, 2002.
21. Zarogoulidis P, Lampaki S, Turner JF, Huang H, Kakolyris S, Syrigos K and Zarogoulidis K: mTOR pathway: A current, upto-date mini-review (Review). Oncol Lett 8: 2367-2370, 2014.